Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

than offset by higher commodity costs which depressed gross margin.

Key Financial Highlights

Net sales for the quarter increased nine percent to $22.0 billion. Volume grew two percent for the quarter driven by Beauty, Fabric Care and Home Care and Baby Care and Family Care segments, including double-digit growth of Gillette Fusion, Head & Shoulders, Cover Girl, Gain and SK-II. Price increases added three percent to net sales. Favorable foreign exchange contributed five percent to sales growth. Disproportionate growth in developing regions and product mix shifts drove a negative one percent mix impact on sales. Organic sales increased five percent for the quarter. Several new initiatives were launched during the quarter including Always Infinity, Tide and Downy Total Care, Crest Pro-Health Whitening Paste, Pampers Swaddlers Sensitive & UnderJams and Dawn Hand Renewal.

Net earnings increased nine percent to $3.3 billion on strong sales growth and higher non-operating gains from planned divestitures. Diluted net earnings per share increased 12 percent for the quarter to $1.03. Operating margin was down 60 basis points due to a commodity-driven decline in gross margin which more than offset lower SG&A expenses as a percentage of sales.

Gross margin declined by 240 basis points to 50.5% during the quarter. Higher commodity and energy costs were partially offset by the impact of price increases and manufacturing cost savings.

SG&A expenses were down 180 basis points for the quarter to 29.2% of net sales primarily due to scale leverage, overhead productivity improvements and the positive impact of foreign transaction gains on working capital balances caused by strengthening of the U.S. dollar late in the quarter.

Operating cash flow was up one percent to $3.3 billion for the quarter behind earnings growth. Free cash flow, defined as operating cash flow less capital expenditures, was $2.6 billion during the quarter and 76% of net e
'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...t. Jude Children,s Research Hospital have demonstr...monia following influenza. They found that the ant...bacteria by inhibiting their protein synthesis, ar...ent with the "beta-lactam" antibiotic ampicillin, ... The finding is important because pneumonia, rathe...
(Date:1/8/2009)..., Jan. 8 Hanger Orthope...nce that throughout the fourth quarter of 2008 it ...er, Rocky Mountain Orthotic-Prosthetics Center, Ri...First Coast Orthotics & Prosthetics, and Ortho...ions add patient care centers to existing markets ...
(Date:1/8/2009)...ed Acquisition in 2009 Continues Growth Trend , ...stCall/ -- IPC The Hospitalist Company, Inc. (Nasd...cian group practice company, announced today that ...t Acute Care Consultants, Inc. (MACC) in St. Louis...xpansion in the St. Louis market, where IPC has es...
(Date:1/8/2009)... Md., Jan. 8 /PRNewswire-Asia/ -- Chindex Internat...pany"), a leading independent American,provider o...People,s Republic,of China, today announced that ...a Conference, to be held in Shanghai on January 12...onference will be held at the Pudong Shangri-,La ...
Breaking Medicine News(10 mins):Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2
...stem, will invest $20 million to establish the wor...India, to provide stem cells for transplant surgeo... a 10% equity stake in this venture and two seats ...nt guidelines are followed, Said company president...
...d occupy greater priority in India due to the ever...chewing practices. There has been a considerable i...n men. // In India and Sri Lanka, where chewing t...verse smoking is practiced, there is a striking in...
...s had a sensitive tooth at some point of their lif... tooth is worn out' or 'you brush in a hard way, s...the Leeds University have come out with a solution... memory. The researchers have developed a solution...
...fund a study which helps to understand the benefit... given to breast cancer patients to ease the pain ...es. The study is to be carried out by Researchers ...will be comparing the three complementary therapy ...
Other Medicine News:Health News:Dental health neglected by over 60 % of Indians 2
(Date:1/7/2009)...PRNewswire/ -- ImQuest Life Sciences announced tod... to the Food and Drug Administration to initiate h...e HIV inhibitor IQP-0410. ImQuest anticipates init...of 2009. IQP-0410 is a novel small molecule inhibi... reverse transcriptase inhibitor (NNRTI). The comp...
(Date:1/7/2009)...uary 7 Circassia Ltd, a specialty,...critical care, today,announced that following suc...s ToleroMune(R) anti-allergy technology, the compa...rther phase II clinical trial in cat allergy. The,... 120 patients with confirmed,cat allergies, and a...
(Date:1/6/2009)...RNewswire/ -- In recent controlled studies conduct..., scientists found that the patented ingredient in...y proven ingredient to increase levels of nitric o...trate/nitrate (NOx) in human subjects. , , Nitr...ease in blood flow to the skeletal muscles. This ...
(Date:1/6/2009)... Cequent Pharmaceuticals, a pionee...RNAi-based treatments to prevent and treat human d...mpleted a successful toxicology study of its candi...peutic targeting the primary oncogene (beta-cateni.... FAP is an inherited gastrointestinal disease tha...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 1Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 2Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 3China Medicine Releases White Paper on Developing Recombinant Aflatoxin Detoxifizyme 23558 1China Medicine Releases White Paper on Developing Recombinant Aflatoxin Detoxifizyme 23558 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 1Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 3Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 1Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 2Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 3Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 4
...Scheduled for Friday, May 4, at 9:00 a.m.,Eastern .../PRNewswire-FirstCall/ --,Medivation, Inc. today a...subgroups of Alzheimer,s disease patients in the C...on showed that both,subgroups were improved compar...acy endpoints studied. , The mean drug-placebo dif...
...hows Promise As an Adjuvant for Vaccines,against A... 07, 2007 /PRNewswire-FirstCall/ -- IR,BioSciences...ata,from its influenza vaccine adjuvant study bein...ates Homspera elevates host,immune responsiveness ...results are from an ongoing study, and are a stron...
Other Medicine Technology:Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 2Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 3Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 4Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 5IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 2IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 3IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 4
...channel within a 12.1mm insertion tube. It featur...d image for improved reliability, an electronic be...5 and 5.0mhz transducer for deeper ultrasound imag...ical orientation and vascular evaluation during re...
...of diagnosis by using the Convex Scanning method. ...od flow by using the Color Flow Mapping and Color ...rated and the balloon fixation has improved. Those...curate techniques. The FG-36UX expands the possibi...
ACL 1000 is an affordable solution for low volume workloads, or as a backup analyzer. The test menu includes a variety of clotting assays, such as Lupus and APCR-V Leiden. The ACL 1000 also offers ba
The SYNCHRON CX5 Delta takes the automation and versatility of the SYNCHRON CX®4 Delta and adds the benefit of electrolyte testing. It's the ideal full-service clinical chemistry system for the l
Medicine Products: